Soluble fibrinogen like protein 2 (sFGL2), the novel effector molecule for immunoregulation

Oncotarget. 2017 Jan 10;8(2):3711-3723. doi: 10.18632/oncotarget.12533.

Abstract

Soluble fibrinogen-like protein 2 (sFGL2) is the soluble form of fibrinogen-like protein 2 belonging to the fibrinogen-related protein superfamily. It is now well characterized that sFGL2 is mainly secreted by regulatory T cell (Treg) populations, and exerts potently immunosuppressive activities. By repressing not only the differentiation and proliferation of T cells but also the maturation of dendritic cells (DCs), sFGL2 acts largely as an immunosuppressant. Moreover, sFGL2 also induces apoptosis of B cells, tubular epithelial cells (TECs), sinusoidal endothelial cells (SECs), and hepatocytes. This mini-review focuses primarily on the recent literature with respect to the signaling mechanism of sFGL2 in immunomodulation, and discusses the clinical implications of sFGL2 in transplantation, hepatitis, autoimmunity, and tumors.

Keywords: autoimmunity; hepatitis; immunoregulation; soluble fibrinogen-like protein 2; transplantation.

Publication types

  • Review

MeSH terms

  • Animals
  • Autoimmune Diseases / genetics
  • Autoimmune Diseases / immunology
  • Autoimmune Diseases / metabolism
  • Autoimmunity
  • Disease Susceptibility
  • Fibrinogen / chemistry
  • Fibrinogen / genetics
  • Fibrinogen / metabolism*
  • Gene Expression Regulation
  • Humans
  • Immunomodulation*
  • Lymphocytes / immunology
  • Lymphocytes / metabolism
  • Signal Transduction*

Substances

  • FGL2 protein, human
  • Fibrinogen